

10/529,858

des Pro³⁶ [Met(O)¹⁴, Trp(O₂)²⁵]Exendin-4 (1-39) (SEQ ID NO: 23),
des Pro³⁶ [Met(O)¹⁴ Trp(O₂)²⁵, Asp²⁸]Exendin-4 (1-39) (SEQ ID NO: 24),
des Pro³⁶ [Met(O)¹⁴ Trp(O₂)²⁵, IsoAsp²⁸]Exendin-4 (1-39) (SEQ ID NO: 25),
des Pro³⁶ [Met(O)¹⁴ Trp(O₂)²⁵, Cyclic imide²⁸]Exendin-4 (1-39) (SEQ ID NO: 26), or
a pharmaceutically acceptable salt or solvate thereof.

LC
4/15/09
Page 12, lines ³⁰⁻³²~~25-28~~:

In one embodiment of the forgoing compounds, each sequence is attached at the N- or C-terminus to the following group: -Lys₆-NH₂ (SEQ ID NO: 106). Preferably, the group is attached to the C-terminus of the sequence.

Page 13, line 1-page 15, line 5:

Additionally specific stabilized Exendin-4 (1-39) compounds include the following sequences:

H-(Lys)₆- des Pro³⁶ [Asp²⁸]Exendin-4(1-39)-Lys₆-NH₂ (SEQ ID NO: 27)
des Asp²⁸ Pro³⁶, Pro³⁷, Pro³⁸Exendin-4(1-39) -NH₂ (SEQ ID NO: 28),
H-(Lys)₆- des Pro³⁶, Pro³⁷, Pro³⁸ [Asp²⁸]Exendin-4(1-39) -NH₂ (SEQ ID NO: 29)
H-Asn-(Glu)₅ des Pro³⁶, Pro³⁷, Pro³⁸ [Asp²⁸]Exendin-4(1-39) -NH₂ (SEQ ID NO: 30),
des Pro³⁶, Pro³⁷, Pro³⁸ [Asp²⁸]Exendin-4(1-39)-(Lys)₆-NH₂ (SEQ ID NO: 31),
H-(Lys)₆- des Pro³⁶, Pro³⁷, Pro³⁸ [Asp²⁸]Exendin-4(1-39)-(Lys)₆-NH₂ (SEQ ID NO: 32),
H-Asn-(Glu)₅- des Pro³⁶, Pro³⁷, Pro³⁸ [Asp²⁸]Exendin-4(1-39)-(Lys)₆-NH₂ (SEQ ID NO: 33),

H-(Lys)₆- des Pro³⁶ [Cyclic imide²⁸]Exendin-4(1-39)-Lys₆-NH₂ (SEQ ID NO: 34)